This Phase I dose-escalation study in patients with advanced solid tumors was performed to determine the MTD, overall safety, pharmacokinetic (PK) profile and anti-tumor activity of afatinib ...
BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...
This single-agent, dose-escalation Phase 1 clinical study is evaluating BDC-3042 in patients with metastatic or unresectable solid tumors including non-small cell lung cancer (NSCLC). Bolt will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback